Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy

Brain

Volumn 133, Issue 8, 2010, Pages 2382-2393

  Brown, Richard G ^a   Lacomblez, Lucette ^b   Landwehrmeyer, Bernard G ^c   Bak, Thomas ^d   Uttner, Ingo ^c   Dubois, Bruno ^e   Agid, Yves ^f   Ludolph, Albert ^c   Bensimon, Gilbert ^g   Payan, Christine ^g   Leigh, Nigel P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cognitive impairment; Multiple system atrophy; Natural history; Outcome; Progressive supranuclear palsy

Indexed keywords

ADULT; AGED; ARTICLE; ATTENTION; CEREBELLUM DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; CONCEPT FORMATION; DISEASE DURATION; DISEASE SEVERITY; DYSAUTONOMIA; EYE DISEASE; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEMORY; PARKINSON DISEASE; PERSEVERATION; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PYRAMIDAL SIGN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SHY DRAGER SYNDROME; AGE; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; AGED; COGNITION DISORDERS; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 77957037904     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq158     Document Type: Article

References (58)

1. Al-Chalabi A, Durr A, Wood NW, Parkinson MH, Camuzat A, Hulot JS, et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009; 4: e7114.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn (Text Revision) (DSM-IV-TR). Washington: American Psychiatric Association; 2000.
3. Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, et al. The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 2005; 26: 108-116.
4. Bak TH, Caine D, Hearn VC, Hodges JR. Visuospatial functions in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 454-456.
5. Bak TH, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005a; 11: 268-273.
6. Bak TH, Rogers TT, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR. Cognitive bedside assessment in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2005b; 76: 420-422.
7. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study. Brain 2009; 132: 156-171.
8. Berent S, Giordani B, Gilman S, Trask CL, Little RJ, Johanns JR, et al. Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy. Brain Cogn 2002; 50: 194-206.
9. Borroni B, Turla M, Bertasi V, Agosti C, Gilberti N, Padovani A. Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. Arch Gerontol Geriatr 2008; 47: 53-61.
10. Burk K, Daum I, Rub U. Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 2006; 21: 772-776.
11. Cotelli M, Borroni B, Manenti R, Alberici A, Calabria M, Agosti C, et al. Action and object naming in frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration. Neuropsychology 2006; 20: 558-565.
12. Cummings JL, Mega M, Gray K, Rosenberg Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
13. Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol 1988; 45: 1194-1199.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-1626.
15. Emre M, Aarsland D, Brown RG, Burn D, Mizuno Y, Broe A, et al. Clinical Diagnostic Criteria for Dementia Associated with Parkinson's Disease. Mov Disord 2007; 22: 1689-1707. (Pubitemid 47597592)
16. Esmonde T, Giles E, Gibson M, Hodges JR. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy. J Neurol 1996; 243: 638-643.
17. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information; 1987. p. 153-164.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
19. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005; 112: 1677-1686.
20. Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006; 21: 179-186.
21. Ghosh BC, Rowe JB, Calder AJ, Hodges JR, Bak TH. Emotion recognition in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2009; 80: 1143-1145.
22. Gilman S, Low PA, Quinn N, Albanese A, Ben Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94-98. (Pubitemid 29155424)
23. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005; 112: 1687-1694.
24. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
25. Guy W. Clinical Global Impressions (CGI). In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services; 1976. p. 218-222.
26. Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003; 18: 1018-1026.
27. Kaat LD, Boon AJ, Kamphorst W, Ravid R, Duivenvoorden HJ, van Swieten JC. Frontal presentation in progressive supranuclear palsy. Neurology 2007; 69: 723-729.
28. Kawai Y, Suenaga M, Takeda A, Ito M, Watanabe H, Tanaka F, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008; 70: 1390-1396.
29. Kitayama M, Kenji WI, Yoshihito I. Assessment of dementia in patients with multiple system atrophy. 2009; 16: 589-594.
30. Krishnan S, Mathuranath PS, Sarma S, Kishore A. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. Neurol India 2006; 54: 268-272.
31. Lange KW, Tucha O, Alders GL, Preier M, Csoti I, Merz B, et al. Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm 2003; 110: 983-995.
32. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997; 120 (Pt 1): 75-90.
33. Lima CF, Meireles LP, Fonseca R, Castro SL, Garrett C. The Frontal Assessment Battery (FAB) in Parkinson's disease and correlations with formal measures of executive functioning. J Neurol 2008; 255: 1756-1761.
34. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.
35. Litvan I, Grafman J, Gomez C, Chase TN. Memory impairment in patients with progressive supranuclear palsy. Arch Neurol 1989; 46: 765-767. (Pubitemid 19182370)
36. Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Kokmen E, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exper Neuropsychol 1998; 20: 536-547.
37. Maher ER, Smith EM, Lees AJ. Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). J Neurol Neurosurg Psychiatry 1985; 48: 1234-1239.
38. Mattis S. Dementia Rating Scale;Professional Manual. Odessa, Fl: Psychological Assessment Resources Inc.; 1988.
39. Meco G, Gasparini M, Doricchi F. Attentional functions in multiple system atrophy and Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 60: 393-398.
40. Milberg W, Albert M. Cognitive differences between patients with progressive supranuclear palsy and Alzheimer's disease. J Clin Exp Neuropsychol 1989; 11: 605-614.
41. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60: 910-916.
42. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, et al. The prevalence of progressive supranuclear palsy (Steele- Richardson-Olszewski syndrome) in the UK. Brain 2001; 124: 1438-1449.
43. O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131: 1362-1372.
44. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 2006; 21: 989-996.
45. Paviour DC, Winterburn D, Simmonds S, Burgess G, Wilkinson L, Fox NC, et al. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase 2005; 11: 274-282.
46. Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Neurology 1986; 36: 1179-1185.
47. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD. Cognitive performance in multiple system atrophy. Brain 1992; 115: 271-291.
48. Robbins TW, James M, Owen AM, Lange KW, Lees AJ, Leigh PN, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994; 57: 79-88.
49. Schwab RS, England AC. Projection technique for evaluating surgery for Parkinson's disease. In: Gillingham FJ, Donaldson MC, editors. Third Symposium on Parkinson's Disease. Edinburgh: E&S Livingstone;1969.
50. Soliveri P, Monza D, Paridi D, Carella F, Genitrini S, Testa D, et al. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000; 69: 313-318.
51. Sullivan EV, De La PR, Zipursky RB, Pfefferbaum A. Neuropsychological deficits accompanying striatonigral degeneration. J Clin Exp Neuropsychol 1991; 13: 773-788.
52. Testa D, Fetoni V, Soliveri P, Musicco M, Palazzini E, Girotti F. Cognitive and motor performance in multiple system atrophy and Parkinson's disease compared. Neuropsychologia 1993; 31: 207-210.
53. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001; 22: 247-251.
54. Vanacore N, Bonifati V, Colosimo C, Fabbrini G, De MG, Marconi R, et al. Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 2001; 22: 101-103.
55. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125: 1070-1083.
56. Wenning GK, Ben Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 68: 434-440.
57. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 (Pt 4): 835-845.
58. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-1258